The Subtilisin-Like Protease Furin Regulates Hemin-Dependent Ectodomain Shedding of Glycoprotein VI

Abstract

Introduction Hemolysis results in release of free hemoglobin and hemin liberation from erythrocytes. Hemin has been described to induce platelet activation and to trigger thrombosis.

Methods We evaluated the effect of hemin on platelet function and surface expression of the platelet collagen receptor glycoprotein VI (GPVI). Isolated platelets were stimulated with increasing concentrations of hemin.

Results We found that hemin strongly enhanced platelet activation, aggregation, and aggregate formation on immobilized collagen under flow. In contrast, we found that surface expression of GPVI was significantly reduced upon hemin stimulation with high hemin concentrations indicating that hemin-induced loss of surface GPVI does not hinder platelet aggregation. Loss of hemin-induced surface expression of GPVI was caused by shedding of the ectodomain of GPVI as verified by immunoblotting and is independent of the GPVI or CLEC-2 mediated ITAM (immunoreceptor-tyrosine-based-activation-motif) signaling pathway as inhibitor studies revealed. Hemin-induced GPVI shedding was independent of metalloproteinases such as ADAM10 or ADAM17, which were previously described to regulate GPVI degradation. Similarly, concentration-dependent shedding of CD62P was also induced by hemin. Unexpectedly, we found that the subtilisin-like proprotein convertase furin controls hemin-dependent GPVI shedding as shown by inhibitor studies using the specific furin inhibitors SSM3 and Hexa-D-arginine. In the presence of SSM3 and Hexa-D-arginine, hemin-associated GPVI degradation was substantially reduced. Further, SSM3 inhibited hemin-induced but not CRP-XL-induced platelet aggregation and thrombus formation, indicating that furin controls specifically hemin-associated platelet functions.

Conclusion In summary, we describe a novel mechanism of hemin-dependent GPVI shedding and platelet function mediated by furin.

Keywords

hemolysis - hemin - platelets - GPVI - shedding

^* A.F. and A.-K.R. are co-first authors.

Authors' Contribution

M.P.G. and A.-K.R. designed and planned the experiments. A.F., M.K., V.D., Z.L., D.S., A.P., X.F. M.F., P.M., and A.-K.R. performed experiments. All the authors participated in the interpretation and discussion of the results. A.F., M.L., O.B., and A.-K.R. analyzed the data including statistical analysis. A.F. and A.-K.R. designed the figures. A.-K.R., A.F., M.P.G., M.K., M.S., T.C., V.D., Z.L., and K.A.L.M. wrote and proof read the article.

Publication History

Received: 01 September 2022

Accepted: 04 March 2023

Article published online:
10 April 2023

• References

• 1 NaveenKumar SK, SharathBabu BN, Hemshekhar M, Kemparaju K, Girish KS, Mugesh G. The role of reactive oxygen species and ferroptosis in heme-mediated activation of human platelets. ACS Chem Biol 2018; 13 (08) 1996-2002
• 2 Schaer DJ, Buehler PW, Alayash AI, Belcher JD, Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013; 121 (08) 1276-1284
• 3 Belcher JD, Chen C, Nguyen J. et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 2014; 123 (03) 377-390
• 4 Kanakiriya SK, Croatt AJ, Haggard JJ. et al. Heme: a novel inducer of MCP-1 through HO-dependent and HO-independent mechanisms. Am J Physiol Renal Physiol 2003; 284 (03) F546-F554
• 5 Sparkenbaugh EM, Chantrathammachart P, Wang S. et al. Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica 2015; 100 (03) 308-314
• 6 Bourne JH, Colicchia M, Di Y. et al. Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica 2021; 106 (02) 626-629
• 7 Hrkal Z, Vodrázka Z, Kalousek I. Transfer of heme from ferrihemoglobin and ferrihemoglobin isolated chains to hemopexin. Eur J Biochem 1974; 43 (01) 73-78
• 8 Nielsen MJ, Møller HJ, Moestrup SK. Hemoglobin and heme scavenger receptors. Antioxid Redox Signal 2010; 12 (02) 261-273
• 9 Oishi S, Tsukiji N, Otake S. et al. Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ. Blood Adv 2021; 5 (07) 2017-2026
• 10 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129 (01) 12-23
• 11 Borst O, Gawaz M. Glycoprotein VI – novel target in antiplatelet medication. Pharmacol Ther 2021; 217: 107630
• 12 Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor?. Blood 2003; 102 (02) 449-461
• 13 Bender M, Hofmann S, Stegner D. et al. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 2010; 116 (17) 3347-3355
• 14 Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood 2004; 104 (12) 3611-3617
• 15 Stephens G, Yan Y, Jandrot-Perrus M, Villeval JL, Clemetson KJ, Phillips DR. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen. Blood 2005; 105 (01) 186-191
• 16 Seizer P, Borst O, Langer HF. et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 2009; 101 (04) 682-686
• 17 Witte A, Rohlfing AK, Dannenmann B. et al. The chemokine CXCL14 mediates platelet function and migration via direct interaction with CXCR4. Cardiovasc Res 2021; 117 (03) 903-917
• 18 Rohlfing AK, Kolb K, Sigle M. et al. ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury. Nat Commun 2022; 13 (01) 1823
• 19 Manke MC, Geue S, Coman C. et al. ANXA7 regulates platelet lipid metabolism and Ca²⁺ release in arterial thrombosis. Circ Res 2021; 129 (04) 494-507
• 20 Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89 (05) 783-787
• 21 Cebo M, Fu X, Gawaz M, Chatterjee M, Lämmerhofer M. Micro-UHPLC-MS/MS method for analysis of oxylipins in plasma and platelets. J Pharm Biomed Anal 2020; 189: 113426
• 22 Manne BK, Getz TM, Hughes CE. et al. Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2). J Biol Chem 2013; 288 (11) 7717-7726
• 23 Morán LA, Di Y, Sowa MA. et al. Katacine is a new ligand of CLEC-2 that acts as a platelet agonist. Thromb Haemost 2022; 122 (08) 1361-1368
• 24 Inoue O, Osada M, Nakamura J. et al. Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: comparison with soluble GPVI. Int J Hematol 2019; 110 (03) 285-294
• 25 Montague SJ, Delierneux C, Lecut C. et al. Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI. Blood Adv 2018; 2 (03) 240-251
• 26 Perrella G, Nagy M, Watson SP, Heemskerk JWM. Platelet GPVI (glycoprotein VI) and thrombotic complications in the venous system. Arterioscler Thromb Vasc Biol 2021; 41 (11) 2681-2692
• 27 Langnau C, Rohlfing AK, Gekeler S. et al. Platelet activation and plasma levels of furin are associated with prognosis of patients with coronary artery disease and COVID-19. Arterioscler Thromb Vasc Biol 2021; 41 (06) 2080-2096
• 28 Leblond J, Laprise MH, Gaudreau S, Grondin F, Kisiel W, Dubois CM. The serpin proteinase inhibitor 8: an endogenous furin inhibitor released from human platelets. Thromb Haemost 2006; 95 (02) 243-252
• 29 Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3 (10) 753-766
• 30 Cheng YW, Chao TL, Li CL. et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep 2020; 33 (02) 108254
• 31 Ascenzi P, Bocedi A, Visca P. et al. Hemoglobin and heme scavenging. IUBMB Life 2005; 57 (11) 749-759
• 32 Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009; 94 (11) 1481-1484
• 33 Ziakas PD, Poulou LS, Rokas GI, Bartzoudis D, Voulgarelis M. Thrombosis in paroxysmal nocturnal hemoglobinuria: sites, risks, outcome. An overview. J Thromb Haemost 2007; 5 (03) 642-645
• 34 Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139 (01) 3-13
• 35 Bergmeier W, Rabie T, Strehl A. et al. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost 2004; 91 (05) 951-958
• 36 Lehmann M, André F, Bellan C. et al. Deficient processing and activity of type I insulin-like growth factor receptor in the furin-deficient LoVo-C5 cells. Endocrinology 1998; 139 (09) 3763-3771
• 37 Mattila SO, Tuhkanen HE, Lackman JJ. et al. GPR37 is processed in the N-terminal ectodomain by ADAM10 and furin. FASEB J 2021; 35 (06) e21654
• 38 Seidah NG. What lies ahead for the proprotein convertases?. Ann N Y Acad Sci 2011; 1220: 149-161
• 39 Seidah NG, Sadr MS, Chrétien M, Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 2013; 288 (30) 21473-21481